Pharmacodynamic profile of tigecycline against methicillin-resistant Staphylococcus aureus in an experimental pneumonia model

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 12, 2009, Pages 5060-5063

  Koomanachai, Pornpan ^a,b   Crandon, Jared L ^a   Banevicius, Mary Anne ^a   Peng, Li ^a   Nicolau, David P ^a  

^a HARTFORD HOSPITAL   (United States)

^b MAHIDOL UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; TIGECYCLINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; BAGG ALBINO MOUSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG HALF LIFE; EXPERIMENTAL MODEL; FEMALE; LUNG LAVAGE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PHARMACODYNAMICS; PNEUMONIA; PREDICTION; PRIORITY JOURNAL; PROTEIN BINDING;

ANIMALS; ANTI-BACTERIAL AGENTS; FEMALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICE; MICE, INBRED BALB C; MINOCYCLINE; PNEUMONIA; STAPHYLOCOCCAL INFECTIONS;

EID: 71249149898     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00985-09     Document Type: Article

References (19)

1. Clinical and Laboratory Standards Institute. 2007. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 7th ed. CLSI document M7-A7 (26)2. Clinical and Laboratory Standards Institute, Wayne, PA.
2. Conte, J. E. Jr., J. A. Golden, M. G. Kelly, et al. 2005. Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline. Int. J. Antimicrob. Agents 25:523-529.
3. Crandon, J. L., M. A. Banevicius, and D. P. Nicolau. 2009. Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model. Antimicrob. Agents Chemother. 53:1165-1169.
4. Crandon, J. L., A. Kim, and D. P. Nicolau. 2009. Tigecycline penetration into the epithelial lining fluid of infected and uninfected murine lungs, abstr. P-228. Abstr. Am. College Clin. Pharm./Eur. Soc. Clin. Pharm. Int. Congr. Clin. Pharm.
5. Crandon, J. L., A. Kim, and D. P. Nicolau. 2009. Comparison of tigecycline penetration into the epithelial lining fluid of infected and uninfected murine lungs. J. Antimicrob. Chemother. 64:837-839.
6. Dowzicky, M. J., and C. H. Park. 2008. Update on antimicrobial susceptibility rates among gram-negative and gram-positive organisms in the United States: results from the Tigecycline Evaluation and Surveillance Trial (TEST) 2005 to 2007. Clin. Ther. 30:2040-2050.
7. Du, X., C. Li, H. K. Sun, C. H. Nightingale, and D. P. Nicolau. 2005. A sensitive assay of amoxicillin in mouse serum and broncho-alveolar lavage fluid by liquid-liquid extraction and reversed-phase HPLC. J. Pharm. Biomed. Anal. 39:648-652.
8. Ellis-Grosse, E. J., T. Babinchak, N. Dartois, et al. 2005. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycinaztreonam. Clin. Infect. Dis. 41(Suppl. 5):S341-S353.
9. Klevens, R. M., M. A. Morrison, J. Nadle, et al. 2007. Invasive methicillinresistant Staphylococcus aureus infections in the United States. JAMA 298:1763.
10. Koomanachai, P., A. Kim, and D. P. Nicolau. 2009. Pharmacodynamic evaluation of tigecycline against Acinetobacter baumannii in a murine pneumonia model. J. Antimicrob. Chemother. 63:982-987.
11. Li, C., C. A. Sutherland, C. H. Nightingale, and D. P. Nicolau. 2005. Quantitation of tigecycline, a novel glycylcycline [corrected] by liquid chromatography. J. Chromatogr. B 819:201.
12. Meagher, A. K., J. A. Passarell, K. Liolios, et al. 2007. Exposure-response analyses of tigecycline efficacy in patients with complicated skin and skin structure infections. Antimicrob. Agents Chemother. 51:1939-1945.
13. Muralidharan, G., M. Micalizzi, J. Speth, et al. 2005. Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. Antimicrob. Agents Chemother. 49:220-229.
14. Nicasio, A. M., J. L. Crandon, and D. P. Nicolau. 2009. In vivo pharmacodynamic profile of tigecycline against phenotypically diverse Escherichia coli and Klebsiella pneumoniae isolates. Antimicrob. Agents Chemother. 53: 2756-2761.
15. Saner, F. H., M. Heuer, P. M. Rath, et al. 2006. Successful salvage therapy with tigecycline after linezolid failure in a liver transplant recipient with MRSA pneumonia. Liver Transpl. 12:1689-1692.
16. Sun, H. K., C. T. Ong, A. Umer, et al. 2005. Pharmacokinetic profile of tigecycline in serum and skin blister fluid of healthy subjects after multiple intravenous administrations. Antimicrob. Agents Chemother. 49:1629-1632.
17. Tanaseanu, C., C. Bergallo, O. Teglia, et al. 2008. Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia. Diagn. Microbiol. Infect. Dis. 61:329-338.
18. van Ogtrop, M. L., D. Andes, T. J. Stamstad, et al. 2000. In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various gram-positive and gram-negative bacteria. Antimicrob. Agents Chemother. 44:943-949.
19. Van Wart, S. A., J. S. Owen, E. A. Ludwig, et al. 2006. Population pharmacokinetics of tigecycline in patients with complicated intra-abdominal or skin and skin structure infections. Antimicrob. Agents Chemother. 50:3701-3707.